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Humans are cumulatively exposed to acetaldehyde from various sources including alcoholic beverages,
tobacco smoke, foods and beverages. The genetic-epidemiologic and biochemical evidence in ALDH2-
deﬁcient humans provides strong evidence for the causal relationship between acetaldehyde-exposure
due to alcohol consumption and cancer of the upper digestive tract. The risk assessment has so far
relied on thresholds based on animal toxicology with lower one-sided conﬁdence limit of the benchmark
dose values (BMDL) typically ranging between 11 and 63 mg/kg bodyweight (bw)/day dependent on
species and endpoint. The animal data is problematic for regulatory toxicology for various reasons (lack
in study quality, problems in animal models and appropriateness of endpoints - especially cancer - for
transfer to humans). In this study, data from genetic epidemiologic and biochemical studies are
reviewed. The increase in the daily exposure dose to acetaldehyde in alcohol-consuming ALDH2-
deﬁcients vs. ALDH2-actives was about twofold. The acetaldehyde increase due to ALDH2 inactivity
was calculated to be 6.7 mg/kg bw/day for heavy drinkers, which is associated with odds ratios of up to 7
for head and neck as well as oesophageal cancer. Previous animal toxicology based risk assessments may
have underestimated the risk of acetaldehyde. Risk assessments of acetaldehyde need to be revised using
this updated evidence.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Acetaldehyde (ethanal) is a compound to which humans are
regularly exposed from multiple sources such as foods, beverages,
cigarettes and the environment (Cavalcante et al., 2005; Feron et al.,
1991; Homann et al., 1997; Lachenmeier et al., 2009b; Lachenmeier
and Sohnius, 2008; Nazaroff and Singer, 2004; Salaspuro, 2009a,
2009b; Uebelacker and Lachenmeier, 2011). Highest exposure re-
sults from consumption of alcoholic beverages and is localized to
mucosal surfaces of the upper digestive tract. This is due to the fact
that after alcohol intake some ethanol is metabolized locally by oral
microbes and mucosal cells to acetaldehyde. Because of the inefﬁ-
cient ability of mucosa and microbes to eliminate acetaldehyde, the
compound accumulates in the saliva and gastric juice (Homann
et al., 1997, 2001; Kurkivuori et al., 2007; Lachenmeier and
Monakhova, 2011; Linderborg et al., 2011; Salaspuro, 2003;
Salaspuro and Salaspuro, 2004; V€akev€ainen et al., 2000, 2001a,nmeier).
r Inc. This is an open access article2001b, 2002). Furthermore, acetaldehyde is found in high con-
centrations in some spirits, but it is also regularly present in wine
and beer (Boffetta et al., 2011; Lachenmeier and Sohnius, 2008;
Linderborg et al., 2008; Paiano et al., 2014).
A point mutation in ALDH2-gene resulting in deﬁcient activity of
the main acetaldehyde metabolizing mitochondrial enzyme
(ALDH2) provides conclusive evidence for the causal relationship
between local acetaldehyde exposure and upper digestive tract
cancer. When drinking alcohol, the upper digestive tract mucosa of
ALDH2-deﬁcients is exposed via saliva to about 2 times and via
gastric juice to 5e6 times higher acetaldehyde concentrations than
in persons with active ALDH2-enzyme (Maejima et al., 2015;
V€akev€ainen et al., 2000, 2001b; Yokoyama et al., 2016; Yokoyama
et al., 2008). Parallel to increased local acetaldehyde exposure,
the risk of ALDH2-deﬁcient alcohol drinkers for oral, pharyngeal,
oesophageal and gastric cancer is many fold compared to alcohol
drinking ALDH2-actives (Boccia et al., 2009; Matsuo et al., 2013;
Tsai et al., 2014; Yang et al., 2010). Moreover, the difference in
cancer risk between ALDH2-deﬁcients and ALDH2-actives in-
creases with increasing alcohol consumption. Thus, ALDH2-under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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aldehyde exposure in the upper digestive tract. Based on newgene-
epidemiological and geneebiochemical evidence, the International
Agency for Research on Cancer (IARC) has reclassiﬁed acetaldehyde
associated with the consumption of alcoholic beverages as a Group
1 human carcinogen (IARC Working Group on the Evaluation of
Carcinogenic Risks to Humans, 2012; Secretan et al., 2009).
For the risk assessment of acetaldehyde, no human data has
been available so far, so that toxicological thresholds based on
animal experiments have been suggested (Lachenmeier et al.,
2009b). Some risk assessment bodies such as the German Federal
Institute for Risk Assessment (BfR, 2010) or the MAK Commission
(2013) have questioned the use of the available animal data for
oral exposure, while other bodies such as the SCCS (2012) used
them to provide quantitative risk estimates and suggest risk man-
agement actions such as implementation of limits in consumer
products such as cosmetics.
ALDH2-deﬁciency provides an entirely new human model for
the quantitative estimation of increased acetaldehyde exposure via
saliva in the upper digestive tract of alcohol drinking ALDH2-
deﬁcients compared to ALDH2-actives. Point mutation in ALDH2
gene has “randomized” millions of alcohol drinkers to abnormally
high acetaldehyde exposure via saliva for decades thus providing a
natural model. Therefore, the intention of this article was to review
the human data that has become available from genetic epidemi-
ological and biochemical research during the last decade and
discuss its relevance for risk assessment.
2. Methods
Data on genetic epidemiological and genetic biochemical
studies regarding the connection between aldehyde dehydroge-
nase 2 (ALDH2)-polymorphism, alcohol consumption, upper
digestive tract cancer and salivary acetaldehyde concentrations in
the presence of ethanol were obtained by a computer-assisted
literature search. Searches were carried out in the PubMed data-
base (U.S. National Library of Medicine, Bethesda, MD). We specif-
ically aimed to identify studies that speciﬁed several dose groups of
alcohol intake and compared ALDH2 active with ALDH2 deﬁcient
individuals, and hence might provide evidence of a clear dose-
response effect.
3. Results
Three studies were identiﬁed that reported about the frequency
of the ALDH2 polymorphism among oesophageal cancer and head
and neck cancer cases and controls according to two variant ALDH2
genotypes [*1*2(deﬁcient) and *1*1(active)] with similar levels of
alcohol intake thus providing dose-response data (Table 1): one
meta-analysis and one study on head and neck cancer (Boccia et al.,
2009; Tsai et al., 2014) and one meta-analysis on oesophageal
cancer (Yang et al., 2010). The data were dichotomized according to
the drinking status of the original studies.
For the estimation of local acetaldehyde exposure via saliva in
different levels of alcohol intake ﬁve studies reporting in vivo
salivary acetaldehyde levels in ALDH2 deﬁcients vs. ALDH2 actives
after alcohol intake were identiﬁed (Maejima et al., 2015;
V€akev€ainen et al., 2000, 2001b; Yokoyama et al., 2016; Yokoyama
et al., 2008). The main characteristics of these studies are pre-
sented in Table 2.
Mean blood and salivary acetaldehyde levels of ALDH2 actives
and deﬁcients after alcohol intake were averaged from the data
presented in each study. In Table 3, salivary acetaldehyde levels
represent sampling time points when ethanol had been evenly
distributed to the whole-body water including saliva after alcoholintake. In three studies the areas under the curve (AUCs) of acet-
aldehyde exposure via saliva during the follow up ranging from 2 to
4 h was either reported or could be calculated. Thereafter differ-
ences in salivary acetaldehyde exposure of ALDH2 actives and de-
ﬁcients were calculated. The average differencewas estimated to be
2.0fold at the sampling time point (5 studies) and according to
AUCs 2.2fold (3 studies) for the deﬁcients vs the actives (Table 3).
The average of 2.1fold was selected for further calculations in
Tables 4 and 5.
For the estimation of exposure of the upper digestive tract
mucosa to acetaldehyde in mg/kg bodyweight (bw)/day, median
unstimulated saliva ﬂow rate was assumed to be 0.5 ml/min
(Fenoll-Palomares et al., 2004). Mean alcohol consumption of
moderate drinkers was assumed to be 3 drinks/day corresponding
to about 4.5 h exposure via saliva (141 ml saliva) to acetaldehyde
(Table 4). The mean alcohol consumption of heavy drinkers and
corresponding exposure to salivary acetaldehyde was assumed to
be 7 drinks (330 ml saliva) per day (Table 4). The additional acet-
aldehyde exposure for ALDH2 deﬁcient compared to ALDH2 active
persons was determined by multiplying the exposure of ALDH2
actives by 2.1 as indicated in Table 3.
Table 5 compares the acetaldehyde daily dose increase with the
odds ratios for the cancer types. It can be deduced that for heavy
drinkers odds ratios ranging from 4 to 7 are associated with acet-
aldehyde dose increases of 6.7 mg/kg bw/day.
Finally, Table 6 summarizes toxicological thresholds for acetal-
dehyde from various literature sources. It can be seen that thresh-
olds based on animal experiments are generally above 10 mg/
kg bw/day. Thresholds based on human epidemiological data are
not yet available and the study data shown in Tables 5 and 6 did not
allow for a dose-response-modelling as none of the study provided
absolute or extra risk data. Nevertheless, the very low acetaldehyde
doses (6.7 mg/kg bw/day) associated with signiﬁcantly increased
odds ratios for cancer, provide plausibility that the human
threshold could lie considerably lower than 0.1 mg/kg bw/day.
4. Discussion
ALDH2-deﬁciency resulting from a single point mutation in
ALDH2-gene is a health risk that passes in frequency familiar hy-
percholesterolemia (FH). The incidence of FH is 1:500 but that of
ALDH2-deﬁciency 1:13. ALDH2-gene mutation took place in South
China over 2000 years ago, and today its carrier frequency is close
to 600 million people of East-Asian descent (Brooks et al., 2009; Li
et al., 2009; Luo et al., 2009). Deﬁcient activity of ALDH2-enzyme
results in decreased ability to detoxify acetaldehyde locally
formed from ethanol and thus provides a unique human model for
increased exposure of upper digestive tract mucosa to acetaldehyde
via saliva after drinking of alcohol (Helminen et al., 2013; Maejima
et al., 2015; V€akev€ainen et al., 2000, 2001b; Yokoyama et al., 2016;
Yokoyama et al., 2008). With increased exposure to salivary acet-
aldehyde, oral, pharyngeal and oesophageal cancer risks of alcohol
drinking ALDH2 deﬁcients are many folds compared to ALDH2
active drinkers, and the higher their alcohol consumption has been
(Boccia et al., 2009; Tsai et al., 2014; Yang et al., 2010).
Acetaldehyde is a cytotoxic, genotoxic and mutagenic com-
pound and carcinogenic in experimental animals (IARC Working
Group on the Evaluation of Carcinogenic Risks to Humans, 2012;
Seitz and Stickel, 2010). In conjunction with the consumption of
alcoholic beverages, acetaldehyde has been reclassiﬁed as carci-
nogenic to humans (Group 1) (IARC Working Group on the
Evaluation of Carcinogenic Risks to Humans, 2012; Secretan et al.,
2009). The new classiﬁcation concerns both the acetaldehyde
formed from ethanol by local microbial and mucosal oxidation as
well as when present in alcoholic beverages.
Table 1
Studies reporting the frequency of the ALDH2 polymorphism among oesophageal cancer (Yang et al., 2010) and head and neck cancer (Boccia et al., 2009; Tsai et al., 2014) cases
and controls according to two variant genotypes [*1*2(deﬁcient) and *1*1(active)] with similar levels of alcohol intake.
Study Cases/controls Never/rare drinkers
Mean alcohol consumption (g/day)
Moderate drinkers
Mean alcohol consumption (g/day)
Heavy drinkers
Mean alcohol consumption (g/day)
Meta-analysis by Yang et al. (2010) a
- Boonyaphiphat et al. (2002) 202/261 Non-drinkers ¼ 0 60 g/day 60 g/day
- Yang et al. (2007) 191/198 Non þ ex-drinkers ¼ 0 1e50 g/day; <5 d/wk >50 g/day; 5 d/wk
- Ding et al. (2009) 221/191 Non-drinkers ¼ 0 >40 g/week e
- Lee et al. (2008) 406/656 Non-drinkers ¼ 0 1-40 g/day >40 g/day
- Yang et al. (2005) 165/494 Non-drinkers ¼ 0 1e50 g/day; <5 d/wk >50 g/day; 5 days/wk.
- Yokoyama et al. (2002) 234/634 Never/rare ¼ 0/1 3-56 g/day >57 g/day
- Yokoyama et al. (2006a) 52/412 Never/rare ¼ 0/1 3-56 g/day >57 g/day
- Chao et al. (2000) 88/327 Rare ¼ 0/1 e >60 g/day
- Yokoyama et al. (2001) 112/526 Rare ¼ 0/1 e >60 g/day (alcoholics)
- Yokoyama et al. (2006b) 42/273 Rare ¼ 0/1 e >60 g/day (alcoholics)
- Matsuo et al. (2001) 102/242 Others? Others? 3 gou/day; 5 days/wkb
SELECTED AVERAGEc <1 g/day ¼ 0 g/day 3 drinks (a 11 g) ¼ 33 g/day 7 drinks (a 11 g) ¼ 77 g/day
Meta-analysis by Boccia et al. (2009) a
- Katoh et al. (1999) 101/147 Never drinkers ¼ 0 1e59 g/day >59 g/day
- Nomura et al. (2000) 191/120 Never drinkers ¼ 0 1e59 g/day >59 g/day
- Asakage et al. (2007) 96/642 Never drinkers ¼ 0 1e59 g/day >59 g/day
- Hiraki et al. (2007) 329/969 Never drinkers ¼ 0 1e59 g/day >59 g/day
- Yokoyama and Omori (2001) 36/847 e 1e59 g/day >59 g/day
SELECTED AVERAGEc <1 g/day ¼ 0 g/day 3 drinks (a 11g) ¼ 33 g/day 7 drinks (a 11 g) ¼ 77 g/day
Tsai et al. (2014) 436/514 Never drinkers ¼ 0 0.1e50 g/day >50 g/day
SELECTED AVERAGEc <1 g/day ¼ 0 g/day 3 drinks (a 11g) ¼ 33 g/day 7 drinks (a 11 g) ¼ 77 g/day
a It is reported that the authors of the original papers have been contacted for missing data.
b 1 Gou ¼ 23 g alcohol.
c Selected average represents the best guess for the median alcohol consumption of never/rare, moderate and heavy drinkers.
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easily binds to various tissue components, including DNA, and
forms carcinogenic adducts both in vitro and in vivo. Increasing
concentrations of acetaldehyde ranging from 25 to 500 mM in the
presence of DNA and polyamines, produce an exponential increase
of mutagenic 1,N2-propanodeoxyguanosine adducts (Theruvathu
et al., 2005). Polyamine synthesis is tightly related to cellular pro-
liferation, with the highest levels being found in rapidly dividing
cells. This is characteristic for the regenerating upper digestive tract
mucosa (Tabor and Tabor, 1984). In human volunteers, low doses of
alcohol have been shown to produce a dose-dependent increase in
acetaldehyde-DNA adducts (N2-ethylidene-dGuo) in the oral cavity
(Balbo et al., 2012). Corresponding doses of alcohol have been
shown to result in 18.7e143.4 mM acetaldehyde levels in saliva
(Homann et al., 1997). In contrast to Balbo et al. (2012) N2-ethyl-
idene-dGuo adducts were not observed in peripheral blood white
cells of human volunteers 48 h after exposure to 150 ml of vodka
(Singh et al., 2012). This discrepancy, however, is not unexpected,
since only very low acetaldehyde concentrations are found in he-
patic venous blood of intoxicated non-alcoholic male Caucasians
(Nuutinen et al., 1984) and acetaldehyde levels are undetectable
(<2 mM) in the peripheral blood (Table 3).
After alcohol intake, several times higher concentrations of
acetaldehyde are found in the saliva than in the blood (Table 3)
(V€akev€ainen et al., 2000, 2001b; Yokoyama et al., 2008). This is due
to the fact that parotid glands, oral microbes and upper digestive
tract mucosal cells are able to oxidize ethanol to acetaldehyde, but
are not sufﬁciently capable for its detoxiﬁcation unlike the liver. The
high local exposure to acetaldehyde formed from ingested ethanol
is in line with epidemiological ﬁndings. In alcohol drinking ALDH2-
deﬁcient individuals compared to ALDH2-actives, the incidence of
those cancers exposed to acetaldehyde derived locally from cellular
and microbial oxidation of ethanol is increased, especially of the
upper digestive tract including stomach (Boccia et al., 2009;
Roerecke et al., 2015; Yang et al., 2010; Hidaka et al., 2014; Wang
et al., 2014; Matsuo et al., 2013). On the contrary, the incidence of
cancers of organs not covered with microbes appears not to beincreased in alcohol drinking ALDH2-deﬁcients compared to
ALDH2-actives e.g. cancers of breast, kidney, liver or the evidence is
contradictory as in the case of pancreas (Kanda et al., 2009; Kawase
et al., 2009; Miyasaka et al., 2005; Yokoyama et al., 1998; Zhou et al.,
2012).
Although only acetaldehyde associated with alcohol consump-
tion has been shown to be carcinogenic to humans, any genotoxic,
mutagenic and carcinogenic compound irrespective of its origin
should concern equal regulatory rules and restrictions (EFSA,
2005). This is particularly true with acetaldehyde that is easily
water and lipid soluble and thus passes readily through cell
membranes. Acetaldehyde probably is one of the most prevalent
human carcinogens. It is present, sometimes in high concentra-
tions, in several alcoholic beverages. It is accumulating in the
digestive tract including saliva, gastric juice and colonic contents
due to its local formation from ethanol by mucosal cells and mi-
crobes (Salaspuro, 2003, 2009a). Tobacco smoking may lead to
considerable exposure, due to the presence of acetaldehyde in the
smoke (Baumung et al., 2016; Cunningham et al., 2011; Salaspuro
and Salaspuro, 2004; Xie et al., 2012), which dissolves into the
saliva and is by that means distributed to the mucosal surfaces of
thewhole upper digestive tract. Moreover, it has also been detected
in smoking cessation products such as electronic cigarettes (Hahn
et al., 2014). Fermented foods such as yoghurt may naturally
contain acetaldehyde, and the substance may also be added to
certain foods as a ﬂavouring compound, especially for its capability
to improve orange ﬂavour (Lachenmeier et al., 2010; Uebelacker
and Lachenmeier, 2011). Acetaldehyde has also been detected in
certain cosmetics (Lachenmeier et al., 2009a; SCCNFP, 2004), as
well as in household and urban air (Bakeas et al., 2003; Nazaroff
and Singer, 2004).
Despite its ubiquitous presence and the expected daily lifetime
intake of humans in industrial societies, the toxicological assess-
ment of acetaldehyde has not reachedmuch attention and there are
no regulatory limits for any of the mentioned products (the only
regulation in the EU for acetaldehyde restricts its migration from
packaging materials such as PET into foods to a certain level
Table 2
Summary of studies about the effect of ALDH2 genotype on salivary acetaldehyde concentrations in the presence of ethanol. ALDH2þ ¼ active aldehyde dehydrogenase
enzyme; ALDH2- ¼ deﬁcient aldehyde dehydrogenase enzyme.
Study Model of alcohol
administration
Salivary acetaldehyde Blood ethanol
and acetaldehyde
Other remarks
1. V€akev€ainen et al. (2000)
- ALDH2þ; n ¼ 13
- ALDH2 -; n ¼ 7
Oral ingestion of ethanol
(0.5 g/kg bw), 10% vol in orange
juice within 20 min
- At 20 min intervals
from 0 to 240 min
- Parotid gland saliva at
60e80 min (three ALDH2þ and ALDH2-)
- AUCsa could be calculated from ﬁgure 1
At 60 min after
alcohol intake
2. V€akev€ainen et al. (2001b)
- ALDH2þ; n ¼ 6
- ALDH2-; n ¼ 5
Oral ingestion of ethanol
(0.4 g/kg bw),10% vol in orange
juice within 20 min
- At 20 min intervals from 0 to 240 min
- AUCs not available
At 60 min after
alcohol intake
The study was repeated after
one week with 4-methylpyrazole
(10e15 mg/kg) 2 h before alcoholb
3. Yokoyama et al. (2008)
- ALDH2þ; n ¼ 12
- ALDH2 -; n ¼ 7
Oral ingestion of alcohol
(0.6 g/kg), 13% vol Calvados,
shochu, red wine or beer
at 3 weeks' intervals
- At 30 min intervals from 0 to 180 min
- AUCs reported in the study
At 30 min intervals
from 0 to 180 min
4. Maejima et al. (2015)
- ALDH2þ; n ¼ 10
- ALDH2 -; n ¼ 10
Intragastric infusion of ethanol
(0.5 g/kg), 15% w/v via
nasogastric tube
- At 30 min intervals from 0 to 120 min
- AUCs reported in the study
Not measured Also gastric juice ethanol and
acetaldehyde levels were analysed
and the effects of PPI-treatment and
slow-release L-cysteine were studiedc
5. Yokoyama et al. (2016)
- ALDH2þ; n ¼ 81
- ALDH2 -; n ¼ 18
Alcoholics in withdrawal
treatment that had stopped
drinking >4 h (mean 10 h)
before saliva sampling
Twice at 1 h intervals
- AUCs could not be calculated
(only 2 time points)
Not measured
6. Helminen et al. (2013) d
- ALDH2þ; n ¼ 11
- ALDH2-; n ¼ 6
Rinsing of mouth with 5 ml
of 40% alcohol for 5 s, after
which the oral contents
were discharged
At 0.5, 2.5, 5, 10, 15 and 20 min
after rinsing
Not measured No differences in salivary acetaldehyde
levels between ALDH2-actives
and edeﬁcients. Presence of ethanol in
systemic blood circulation is required
for the elevation of salivary acetaldehyde
among ALDH2-deﬁcients
a AUC ¼ area under the salivary acetaldehyde curve of ALDH2-actives and -deﬁcients.
b 4-Methylpyrazole (4 MP) is an effective inhibitor of alcohol dehydrogenase (ADH) enzyme of somatic cells. Its inhibitory effect on microbial ADH enzymes, however, is
poor.
c PPIs are powerful gastric acid secretion inhibitors resulting in microbial colonization of the gastric contents. PPI-inhibitor rabeprazole 10 mg b.i.d. was administered for 7
days before the experiments with or without slow-release L-cysteine. L-cysteine binds effectively to acetaldehyde and inactivates its reactive aldehyde group.
d Excluded, since only local acetaldehyde formation in the mouth was studied. No ethanol was delivered to saliva via systemic blood circulation.
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can be probably explained historically because acetaldehyde
received the ‘generally recognized as safe’ (GRAS) status by the
Flavor and Extract Manufacturers Association (FEMA) in 1965 (Hall
and Oser, 1965). This status was corroborated by the Joint FAO/
WHO Expert Committee on Food Additives (JECFA) in 1998 (JECFA,
1998). However, in the case of acetaldehyde, the application of
JECFA's decision tree for ﬂavouring substances includes a crucial
misconception with regard to acetaldehyde's metabolism (WHO,
2000). Because of the lack of low Km aldehyde dehydrogenase en-
zymes in the oral mucosa, acetaldehyde accumulates in the pres-
ence of ethanol in the saliva and is not metabolized into innocuous
products in the oral cavity (Dong et al., 1996). Via saliva, carcino-
genic acetaldehyde is distributed to the mucosal surfaces of the
mouth, oesophagus and stomach.
As a matter of fact, a large body of evidence has been acquired
over the last decade thatmay question these early risk assessments.
Speciﬁcally, the evidence for carcinogenic and genotoxic effects of
acetaldehyde has been improved leading the International Agency
for Research on Cancer to assign acetaldehyde into group 2B as
being ‘possibly carcinogenic to humans’ in 1987 and 1999 (IARC,
1987; IARC Working Group on the Evaluation of Carcinogenic
Risks to Humans, 1999), while it was upgraded in association
with alcohol consumption into group 1 (i.e., the highest level of
evidence) in 2009 (IARC Working Group on the Evaluation of
Carcinogenic Risks to Humans, 2012; Secretan et al., 2009).
The differences in the order of magnitude of toxicological
threshold values for acetaldehyde between animal experiments
and human epidemiology are not unexpected. In this study, human
data was restricted to upper digestive tract cancers i.e. on the local
carcinogenic potential of acetaldehyde. With regard toacetaldehyde, the use of human data has several advantages as
compared to animal data. In animal model studies with rodents,
acetaldehyde has been administered without the presence of
ethanol, but only acetaldehyde associated with alcoholic beverages
has been classiﬁed as human group 1 carcinogen. Gastrointestinal
tract mucosa of rodents is known to be able to metabolize both
ethanol and acetaldehyde (Koivisto and Salaspuro, 1996; Pronko
et al., 2002). Without the competing presence of ethanol, some of
the acetaldehyde given to rodents in drinking water is metabolized
by mucosal cells and the rest of it completely by the liver to acetate
(Matysiak-Budnik et al., 1996). Thus, the ﬁrst-pass metabolism of
acetaldehyde mediated mostly by the liver totally eliminates
possible systemic effects of acetaldehyde via blood circulation to
other organs.
The BfR (2010) remarked in their criticism of the dose-response
relationship in the oral lifetime rat feeding study of Soffritti et al.
(2002) that the statistical power has not been sufﬁcient for the
relevant endpoints to evaluate the acetaldehyde carcinogenicity
such as tumours of the oral cavity and oesophagus. Therefore, they
expected the toxicological threshold to be below the ﬁrst dose (i.e.
5 mg/kg bw/day) or lower. In light of the sensitivity of the animal
tests alone, the lower results in humans appear plausible.
Using a unique genetic human model for increased local acet-
aldehyde exposure of the upper digestive tract has major advan-
tages over animal data. Nature has randomized millions of alcohol
drinking persons to different quantities of acetaldehyde exposure.
This type of human model based on a single point mutation is not
available for any other of the 119 IARC group 1 carcinogens. The
model makes it possible to minimize the effect of important con-
founding factors such as smoking, diet, oral hygiene, HPV, different
beverages, drinking habits, BMI and under reporting that are
Table 3
Mean blood and salivary acetaldehyde levels of ALDH2-actives (ALDH2þ) compared to ALDH2-deﬁcients (ALDH2-) after oral intake of alcohol. Difference in salivary acetaldehyde exposure was calculated in twoways: 1. Salivary
acetaldehyde concentration at sampling time point of ALDH2-deﬁcients was divided by that of ALDH2-positives. 2. Area under the curve (AUC) of the salivary acetaldehyde curves during the follow-up period (2e4 h) of ALDH2-
deﬁcients was divided by that of ALDH2-positives.
Study Blood acetaldehyde Salivary acetaldehyde Salivary ethanol level at
sampling time point mM/‰
Difference in salivary acetaldehyde
exposure
ALDH2-/ALDH2þ
ALDH2þ
(mM / mg/l)
(means)
ALDH2-
(mM / mg/l)
(means)
ALDH2þ
(mM / mg/l)
(means)
ALDH2-
(mM / mg/l)
(means)
At sampling time point According to AUC
1. V€akev€ainen et al. (2000) a Not detectable 6.6/0.29
(at 60 min)
26/1.1
(at 60 min)
58/2.6
(at 60 min)
z12/z0.55
(at 60 min)
2.3fold
(at 60 min)
2.3fold
2. V€akev€ainen et al. (2001b) b Not detectable 6.4/0.28
(at 60 min)
12, 17, 20/0.53, 0.75, 0.89
(at ethanol levels of 4,6,8 mM)
19, 27, 33/1.45, 1.19, 1.45
(at ethanol levels of 4,6,8 mM)
4, 6, 8/0.19, 0.28, 0.37 1.5fold
(mean)
3. Yokoyama et al. (2008) z2/0.09
(at 90 min)
z10/0.44
(at 90 min)
30/1.32
(at 90 min)
52/2.29
(at 90 min)
z12/z0.55
(at 90 min)
1.7fold
(at 90 min)
1.6fold
4. Maejima et al. (2015) c Not measured Not measured 6/0.26
(at 60 min)
16/1.06
at (60 min)
z15/z0.63
(at 60 min)
2.7fold
(at 60 min)
2.7fold
5. Yokoyama et al. (2016) d Not measured Not measured 41/1.80 73/3.20 21/ 1 1.8fold
MEAN 25/1.1e 46/2.1e 2.0fold 2.2fold
Remarks - In ALDH2-actives in general
under the limit of detection
- In ALDH2-deﬁcients low
levels ranging from 6.4 to
z12 mM (0.28e0.53 mg/l)
- Levels in saliva are several times higher than in blood
- In ALDH2-deﬁcients levels are 1.5e2.3fold higher than in
ALDH2-actives
Salivary ethanol levels range from
very low 2e4 mM to very high 61 mM
The difference in salivary acetaldehyde
exposure between ALDH2-actives and
edeﬁcients appears to be equal when
averaged either from single sampling time
points or from AUCs.
Mean 2.1 was selected for further
calculations in Tables 4 and 5
a Acetaldehyde levels of sterile parotid gland saliva were undetectable in three ALDH2-actives and 75.0, 21.8 and 3.9 mM in three ALDH2-deﬁcients. Suggests that additional salivary acetaldehyde in ALDH2-deﬁcients is derived
from salivary glands.
b 4-Methylpyrazole (ADH inhibitor) treatment inhibited totally the increase in salivary acetaldehyde among ALDH2-deﬁcients but had no effect on salivary acetaldehyde in ALDH2-actives. Suggests that additional salivary
acetaldehyde in ALDH2-deﬁcients is derived from salivary glands.
c Alcohol was infused intragastrically that may result in lower salivary acetaldehyde levels. Nevertheless, differences in salivary acetaldehyde levels between ALDH2-actives and -deﬁcients were comparable to those found in
other studies.
d In line with earlier ﬁndings, higher salivary ethanol levels result in higher salivary acetaldehyde levels. This is caused by the kinetics of different microbial alcohol dehydrogenase enzymes.
e The signiﬁcance of differences in salivary acetaldehyde levels between ALDH2-actives and edeﬁcients. Study 1: p < 0.001; Study 2: p < 0.001; Study 3: p < 0.0001; Study 4: p¼ 0.009 for AUC; Study 5: p¼ 0.0008. In study 2,
the acetaldehyde level at 8 mM ethanol was used for the calculation of the mean.
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Table 5
Summary of data from genetic epidemiological studies regarding the cancer risk of ALDH2-deﬁcient people in connection with alcohol consumption.
Drinking status Acetaldehyde daily dose increase due to ALDH2 inactivity (mg/kg bw/day)a Odds Ratio (LCI/UCI) (ALDH2-deﬁcient compared to active)
1. Yang et al. (2010) (oesophageal cancer in Japan and China)
Never drinkers 0 1.28 (0.91/1.80)
Moderate
Drinkers
2.9 3.12 (1.95/5.01)
Heavy Drinkers 6.7 7.12 (4.67/10.86)
2. Boccia et al. (2009) (head and neck cancer in Japan)
Never drinkers 0 0.97 (0.65/1.46)
Moderate
Drinkers
2.9 1.68 (1.27/2.22)
Heavy Drinkers 6.7 3.57 (1.41/9.05)
3a. Tsai et al. (2014) (head and neck cancer in Taiwan)
(fast ADH1B(*2*2); slow ALDH2(*1*2 þ *2*2)
0 g 0 1.00
0.1e50 g 2.9 2.61 (1.19/5.75)b
>50 g 6.7 7.28 (2.00/26.49)b
3b. Tsai et al. (2014) (head and neck cancer in Taiwan)
(slow ADH1B(*1*1 þ *1/*2); slow ALDH2(*1*2 þ *2*2)
0 g 0 1.00
0.1e50 g 2.9 1.99 (0.92/4.34)b
>50 g 6.7 7.09 (2.88/17.42)b
a Authors estimation based on data shown in Tables 2e4.
b The results indicate that fast ADH enzyme does not correlate with increased head and neck cancer risk among ALDH2-deﬁcients. This is in accordance with no effect of fast
ADH on salivary acetaldehyde levels in the presence of ethanol in ALDH2-deﬁcient alcoholics (Yokoyama et al., 2016).
Table 4
Calculation of the exposure of upper digestive tract mucosa to acetaldehyde via saliva in ALDH2-actives and -deﬁcients.
Acetaldehyde exposure via saliva Never/rare drinkers
(see Table 1)
Moderate drinkers
(see Table 1)
(3 drinks ¼ 33 g/day)
Heavy drinkers
(see Table 1)
(7 drinks ¼ 77 g/day)
Exposure time 0 4.7 h/daya 11 h/daya
Amount of saliva secreted 141 ml/dayb 330 ml/dayb
ALDH2-actives
- in mg/l 0 1.1c 1.1
- in mg/day 0 155 363
- in mg/kg bw/dayd 0 2.6 6.1
ALDH2-deﬁcientse
- in mg/l 0 2.3 2.3
- in mg/day 0 326 762
- in mg/kg bw/dayd 0 5.5 12.8
Acetaldehyde daily dose increase due to ALDH2-deﬁciencyf
- in mg/kg bw/dayd 0 2.9f 6.7f
a Acetaldehyde exposure time is 1.5 h/drink (1 drink ¼ 11 g ethanol) based on the normal elimination rate of ethanol (7 g/h) (Cederbaum, 2012).
b Unstimulated saliva ﬂow rate is assumed to be 0.5 ml/min (Fenoll-Palomares et al., 2004).
c 1.1 mg/l is calculated as indicated in Table 3.
d Mean weight ¼ 60 kg.
e x 2.1 (Table 3).
f ALDH2 def. e ALDH2 act.
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alcohol and cancer. Among ALDH2-deﬁcient and ALDH2-active
individuals these important confounding factors can be assumed
to be more or less evenly distributed.5. Conclusions
Our data based on human epidemiology corroborate the ﬁnd-
ings of previous studies based on animal toxicology (see overview
in Table 6) in the fashion that these studies at least have not
overestimated the risk of acetaldehyde. The unique human gene-
eepidemiological and geneebiochemical evidence, even if limited
by some uncertainty, points in the direction that the risk of acet-
aldehyde has been underestimated rather than overestimated.
In light of this evidence, it is commendable that the European
Commission has recently stated that they will raise the issue of
acetaldehyde with the competent authorities of the member statesand, if appropriate, the European Food Safety Authority (EFSA) will
be requested to assess the risk for human health related to the
presence of acetaldehyde in food as process contaminant or as
natural ﬂavour (Borg, 2014). We basically agree with this assess-
ment of the commission and clearly believe in a considerable
appropriateness of an EFSA assessment, however, we think that
the addition of acetaldehyde as artiﬁcial ﬂavour to foods, which
still is a common and legal practice, might speciﬁcally require
scrutiny. It must be noted that the German Federal Institute for
Risk Assessment remarked in 2010 that the safety of acetaldehyde
when used as ﬂavouring substance cannot be ﬁnally evaluated
(BfR, 2010). This raises the question why potentially unsafe ﬂavour
additives may be used in foods prior to the proof of their safety by
adequate studies conducted by the industry. There is currently no
evidence that acetaldehyde present in ‘non-alcoholic’ foods and
beverages is more safe than acetaldehyde associated with the use
of alcoholic beverages.
Table 6
Summary of toxicological thresholds (benchmark doses) for acetaldehyde.
Study containing the original
experimental data
Study with dose-response modelling
to establish thresholds
Species/Route/Study type Endpoint BMD a
(mg/kg bw/day)
BMDL b
(mg/kg bw/day)
Yang et al. (2010) This study Humans/oral/
epidemiology
Oesophageal cancer z<0.1 c z<0.1 c
Boccia et al. (2009) This study Humans/oral/
epidemiology
Head and neck cancer z<0.1 c z<0.1 c
Tsai et al. (2014) This study Humans/oral/
epidemiology
Head and neck cancer z<0.1 c z<0.1 c
Soffritti et al. (2002) Lachenmeier et al. (2009b) Rats/oral/lifetime Tumour-bearing animals, M 114 56
Soffritti et al. (2002) Lachenmeier et al. (2009b) Rats/oral/lifetime Total malignant tumours, M 58 41
Soffritti et al. (2002) Lachenmeier et al. (2009b) Rats/oral/lifetime Total malignant tumours, F 152 d 63 d
Woutersen et al. (1986) Xie et al. (2012) Rats/inhalation/27 months Nasal squamous cell
carcinomas, M
15 e 11 e
Sanner et al. (2001) Sanner et al. (2001) (no data provided) (no data provided) (no data provided) 15.5 f
Unclear; several studies
(Woutersen et al. (1986);
Woutersen and Feron (1987);
including pers. comm.)
Gold et al. (2007) Unclear (Rats/inhalation
/26 months)
Unclear (Nose and larynx cancer) (no data provided) 17.4
Unclear; Feron et al. (1982)
and pers. comm.
Gold et al. (2007) Unclear (Hamsters/
inhalation/52 weeks)
Unclear (Larynx cancer) (no data provided) 41.9
a BMD: benchmark dose. The benchmark response was 10% in the animal studies.
b BMDL: lower one-sided conﬁdence limit of the BMD.
c The available data do not allow for BMDmodelling. However, the values are estimated as considerably being below 0.1 mg/kg bw/day (compare exposure data in Table 5).
d Non-signiﬁcant model.
e The BMC and BMCL in mg/m3 were re-calculated to BMD/BMDL using the following conversion of (SCCNFP, 2004): BMD (mg/kg bw/day) ¼ BMC (mg/m3)/9. This formula
considers an inhalation rate of 20.5 l/h and an exposure time of 6 h/d, 5 d/week for 27 months.
f Calculated from LED1 value (1.55) by multiplication with 10.
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